Search clinical trials for: GSK2857916

Total 14 results

GlaxoSmithKline

Recruiting

A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function (DREAMM12)

Multiple Myeloma

United States, Greece, Korea, Republic of, Singapore
University of Pennsylvania
GlaxoSmithKline

Recruiting

Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma

Myeloma

United States
GlaxoSmithKline

Terminated

Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM

Relapsed/Refractory Multiple Myeloma

Australia, Sweden, Canada
GlaxoSmithKline

Completed

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916

Multiple Myeloma

United States, Canada, United Kingdom
GlaxoSmithKline

Recruiting

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (DREAMM-20)

Multiple Myeloma

Australia, Poland, Taiwan, Korea, Republic of, Japan, United Kingdom, Brazil, Mexico, Turkey, Argentina
GlaxoSmithKline

Available

Expanded Access Request Program for Belantamab Mafodotin (GSK2857916) in Multiple Myeloma

Multiple Myeloma
Roswell Park Cancer Institute
GlaxoSmithKline

Recruiting

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

Plasma Cell Myeloma

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment

Multiple Myeloma

United States
Massachusetts General Hospital
Sanofi; GlaxoSmithKline

Not yet recruiting

Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma (ISABELA)

Multiple Myeloma | Refractory Multiple Myeloma | Relapsed Cancer

United States
Canadian Myeloma Research Group
GlaxoSmithKline

Recruiting

Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex

Relapsed and/or Refractory Multiple Myeloma

Canada
Mayo Clinic

Recruiting

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
Multiple Myeloma Research Consortium
Eli Lilly and Company; GlaxoSmithKline; AbbVie; Takeda; Genentech, Inc.; Celgene Corporation and other collaborators

Recruiting

Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG)

Relapsed Refractory Multiple Myeloma

United States
Emory University
National Cancer Institute (NCI); GlaxoSmithKline

Recruiting

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

Plasma Cell Myeloma

United States
Mayo Clinic

Completed

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States

3

Subscribe